Английская Википедия:Indacaterol/mometasone

Материал из Онлайн справочника
Версия от 18:02, 25 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Combination drug}} {{Use American English|date=July 2020}} {{Use dmy dates|date=June 2020}} {{Infobox drug | drug_name = | type = combo | image = | width = | alt = | image2 = | width2 = | alt2 = | caption = <!-- Combo data --> | component1 = Indacat...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Infobox drug

Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2 agonists.[1]

The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).[1] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.[1] Indacaterol/mometasone was approved for medical use in the European Union in May 2020,[1] and in Japan in June 2020.[2]

References

Шаблон:Reflist

External links

Шаблон:Adrenergic agonists Шаблон:Asthma and copd rx Шаблон:Glucocorticoids and antiglucocorticoids Шаблон:Glucocorticoid receptor modulators Шаблон:Portal bar Шаблон:Respiratory-system-drug-stub

  1. 1,0 1,1 1,2 1,3 Шаблон:Cite web Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. Шаблон:Cite press release